Results 41 to 50 of about 92,853 (340)

Digoxin improves steatohepatitis with differential involvement of liver cell subsets in mice through inhibition of PKM2 transactivation.

American Journal of Physiology - Gastrointestinal and Liver Physiology, 2019
T The cardiac glycoside digoxin was identified as a potent suppressor of PKM2-HIF-1a pathway activation in liver injury mouse models via intraperitoneal injection.
P. Zhao, Sheng-Na Han, Suyavaran Arumugam, M. Yousaf, Yan-qin Qin, Joy X. Jiang, Natalie J Torok, Yonglin Chen, M. S. Mankash, Junbao Liu, Jiansheng Li, Y. Iwakiri, Xinshou Ouyang   +12 more
semanticscholar   +1 more source

Synchronization modulation increases transepithelial potentials in MDCK monolayers through Na/K pumps [PDF]

, 2013
Peer reviewedPublisher ...
A Huttenlocher, AC Vieira, AV Ljubimov, B Reid, B Robertson, B Song, B Song, B Vanhaesebroeck, Benjamin Lee, CD McCaig, CD McCaig, CJ Taylor, CM Festen, D Yu, DM Bryant, DM Maurice, E Mayhew, EH Larsen, EH Serpersu, Hanqing Li, Hong-Long (James) Ji, J Dube, J Teissie, J Zak, JG Hayes, JP Lavelle, KM Madsen, L Shoshani, L Zhang, Lin Cao, LP Zhang, M Blank, M Blank, M Chiang, M Gekle, M Nakao, M Zhao, M Zhao, MD Laughery, Michelle So, Min Zhao, MR Knowles, N Montalbetti, N Montalbetti, OA Candia, PD Wilson, PG Lawrence, R Dando, R Dando, R Kucerova, R Nuccitelli, RC Valente, RF Rakowski, RF Rakowski, SA Rajasekaran, SD Klyce, TC Chinet, TD Xie, VS Markin, Vu Tran, W Chen, W Chen, W Chen, W Chen, W Chen, W Chen, Wei Chen, WS Marshall, X Leschelle, Xiaodong Zhang, Yaohui Sun   +70 more
core   +4 more sources

Population pharmacokinetic analysis and dosage recommendations for digoxin in Japanese patients with atrial fibrillation and heart failure using real-world data

BMC Pharmacology and Toxicology, 2022
Background Digoxin is an important treatment option for reducing the ventricular rate in patients with atrial fibrillation (AF) and heart failure (HF). Digoxin has a narrow therapeutic window and large interindividual variability.
Toshinori Hirai, Hidefumi Kasai, Miyoko Naganuma, Nobuhisa Hagiwara, Tsuyoshi Shiga   +4 more
doaj   +1 more source

In vitro Removal of Therapeutic Drugs with a Novel Adsorbent System [PDF]

, 2002
Background/Aim: Substances in the middle molecular weight range have been shown to play a significant pathogenetic role in as diverse disorders as end-stage renal disease and multiple organ failure.
Bellomo, Rinaldo, Bordoni, Valeria, D'Intini, Vincent, Dall'Olio, Giuliano, Galloni, Elisabetta, Reiter, Karl, Ricatti, Maria Grazia, Ronco, Claudio, Ruperti, Salvatore, Soffiati, Giuliano, Soli, Maurizio   +10 more
core   +1 more source

Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp. [PDF]

PLoS ONE, 2013
We have reported that the P-gp substrate digoxin required basolateral and apical uptake transport in excess of that allowed by digoxin passive permeability (as measured in the presence of GF120918) to achieve the observed efflux kinetics across MDCK-MDR1-
Annie Albin Lumen, Libin Li, Jiben Li, Zeba Ahmed, Zhou Meng, Albert Owen, Harma Ellens, Ismael J Hidalgo, Joe Bentz   +8 more
doaj   +1 more source

Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials

PLoS ONE, 2018
Background During recent years, systematic reviews of observational studies have compared digoxin to no digoxin in patients with atrial fibrillation or atrial flutter, and the results of these reviews suggested that digoxin seems to increase the risk of ...
N. Sethi, E. Nielsen, Sanam Safi, J. Feinberg, C. Gluud, J. Jakobsen   +5 more
semanticscholar   +1 more source

Digoxin Is Associated With a Decreased Incidence of Angiodysplasia-Related Gastrointestinal Bleeding in Patients With Continuous-Flow Left Ventricular Assist Devices

Circulation: Heart Failure, 2018
Background Gastrointestinal bleeding (GIB) is one of the principal adverse events affecting patients with continuous-flow left ventricular assist devices (CF-LVADs).
S. Vukelic, P. Vlismas, Snehal R. Patel, X. Xue, Sanyog G. Shitole, O. Saeed, D. Sims, T. Chinnadurai, Julia J. Shin, S. Forest, D. Goldstein, U. Jorde   +11 more
semanticscholar   +1 more source

Mihai Gheorghiade, MD-Life and Concepts [PDF]

, 2018
How do you capture an idea, shape it, and then bring it into the world? Of his many talents, this ability was a fundamental characteristic of Mihai Gheorghiade.
Butler, Javed, Chioncel, Ovidiu, Collins, Sean P., Pang, Peter S.   +3 more
core   +1 more source

Digoxin and Heart Failure: Are We Clear Yet?

Cardiovascular Innovations and Applications, 2017
The Digoxin Investigation Group trial has multiple flaws in the trial design for the findings to be universally applicable. Digoxin in low serum concentrations (0.5–0.9 ng/mL) has been shown to decrease mortality in heart failure patients.
Amit Gupta, Melissa Dakkak, Alan Miller
doaj   +1 more source

The effect of calcium in water hardness on digoxin plasma levels in an experimental rat model [PDF]

ARYA Atherosclerosis, 2020
BACKGROUND: Digoxin is a drug for ventricular rate control in atrial fibrillation (AF). The major challenge in digoxin therapy is to adjust the appropriate concentration range for this drug due to its narrow therapeutic index.
Shabnam Shahsavand, Mohammad Moshirfar, Seyed Hassan Seyed-Sharifi, Mohammad Amin Younessi-Heravi, Reza Ghasemi, Morteza Valaei, Mohsen Yaghubi   +6 more
doaj   +1 more source